Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1

Interventions

Rituximab 23Cyclophosphamide 17Bortezomib 15Filgrastim 14Peripheral Blood Stem Cell Transplantation 13fludarabine phosphate 10Etoposide 10Vincristine 8Radiotherapy 8Cyclosporine 8tanespimycin 7Prednisone 7alvocidib 6Vorinostat 6Ifosfamide 6Doxorubicin 6Cytarabine 6Melphalan 5Lenalidomide 5Busulfan 5temsirolimus 4sargramostim 4bryostatin 1 4Paclitaxel 4Methotrexate 4Magnetic Resonance Spectroscopy 4Interferon-alpha 4Gemcitabine 4Dexamethasone 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Lymphoma, Mantle-Cell × Methylprednisolone Acetate × Clear all
NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡